XNASPRTG
Market cap6mUSD
Dec 23, Last price
5.39USD
1D
-9.56%
1Q
-21.08%
Jan 2017
-58.54%
IPO
-77.54%
Name
Portage Biotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.37%
Rev. gr., 5y
%
Revenues
0k
Net income
-75m
L-27.98%
CFO
-14m
L+18.42%
Earnings
Feb 26, 2025
Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 18,253 | 16,575 | 15,588 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (18,253) | (16,575) | (15,588) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (10,548) | (17,856) | 4,352 | |||||||
Tax Rate | ||||||||||
NOPAT | (7,705) | 1,281 | (19,940) | |||||||
Net income | (75,339) -27.98% | (104,611) 445.73% | (19,169) 11.52% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,028 | 2,982 | 29,093 | |||||||
BB yield | -52.61% | -5.99% | -33.91% | |||||||
| Debt | ||||||||||
Debt current | 40 | |||||||||
Long-term debt | 54 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,564 | 11,305 | ||||||||
Net debt | (4,934) | (13,438) | (32,434) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (14,297) | (12,073) | (6,764) | |||||||
CAPEX | (3) | |||||||||
Cash from investing activities | 2,812 | (617) | ||||||||
Cash from financing activities | 5,968 | (117) | 27,346 | |||||||
FCF | (9,105) | 3,343 | (20,637) | |||||||
| Balance | ||||||||||
Cash | 5,028 | 10,545 | 23,352 | |||||||
Long term investments | 2,893 | 9,082 | ||||||||
Excess cash | 5,028 | 13,438 | 32,434 | |||||||
Stockholders' equity | 3,329 | 54,191 | 148,506 | |||||||
Invested Capital | 1,611 | 73,262 | 133,000 | |||||||
ROIC | 1.24% | |||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 20,340 | 16,119 | 13,060 | |||||||
Price | 0.56 -81.77% | 3.09 -52.97% | 6.57 -76.51% | |||||||
Market cap | 11,458 -77.00% | 49,808 -41.95% | 85,804 -73.85% | |||||||
EV | 5,831 | 35,720 | 97,599 | |||||||
EBITDA | (18,199) | (16,574) | (15,588) | |||||||
EV/EBITDA | ||||||||||
Interest | 32 | 9 | 43 | |||||||
Interest/NOPBT | ||||||||||